Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taste Assessment of Ozanimod in Healthy Subjects
NCT05001152Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ozanimod in multiple sclerosis (MS) and ulcerative colitis (UC), sponsored by Bristol Myers Squibb. Primary endpoints: Taste evaluation - Aromatic identity up to 6 months, Taste evaluation - Amplitude up to 6 months and 2 more. Started Sep 2021; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05001152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001152.